Main Article Content

Abstract

Le Purpura thrombopénique immunologique (PTI) est une des principales causes de thrombopénie de l’enfant. Nous reportons le cas d’un nourrisson de douze mois présentant un PTI compliqué d’anémie sévère. La prise en charge du PTI est bien codifiée avec une évolution favorable. Le but de ce rapport est de rappeler dans notre contexte un diagnostic pas très souvent évoqué du fait de la couleur de la peau qui rend les pétéchies invisibles et peut entraîner des décès en cas de saignements extériorisés aigus importants.

Article Details

How to Cite
Pondy Ongotsoyi, A. H., Foe Mba, M., & Kuate Makowa, L. M. (2019). Purpura Thrombopénique Immunologique : à propos d’un Cas au Centre Mère et Enfant de la Fondation Chantal Biya. HEALTH SCIENCES AND DISEASE, 20(6). https://doi.org/10.5281/hsd.v20i6.1680

References

  1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med.2002;346:995-1008.
  2. Pupuras. P Chastagner hématologie de l’enfant p 244-260 Flammarion Médecine Sciences 1995
  3. Raymond G Watts, idiopathic thrombocytopenic purpura : a ten year natural history study at children hospital of alabama, clinical pediatrics, october 2004.
  4. Roberto Stasi, Maria LauraEvangelista ,ElisaStipa ,FrancescoBuccisano ,Adriano Venditti,Sergio Amadori. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management, 2008 Schattauer GmbH,Stuttgar.
  5. Bolton-Maggs. Idiopathic thrombocytopenic purpura, Handbook of Pediatric Hematology and Oncology Arch Dis Child2000;83:220–222 et.
  6. Lilleyman JS. Management of childhood idiopathic throm-bocytopenic purpura.Br J Haematol1999;105:871–5].
  7. Blanchette et Bolton Maggs. childhood immune thrombocytopenic purpura : diagnosis and management. Pediatr Clin N Am (2008) 393-420.
  8. George JN, Woolf SH, Raskob GE, et al. Idiopathic thromboctyopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40
  9. Purpura thrombopénique de l’adulte et de l’enfant : protocole national de diagnostic et de soins. HAS, 2009. https://www.orpha.net/data/patho/Pro/fr/PNDS_
  10. Desiree Medeiros, George R. Buchanan. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome. The journal of pediatrics september 1998, volume 133, number 3
  11. Brigitte Némirovsky. Leucémies aiguës de l’enfant et de l’adolescent. Parcours de soins, le Concours médical, Tome 137 | n° 9 | Novembre 2015
  12. Halperin DS, Doyle JJ. Is bone marrow examination justified in idiopathic thrombocytopenic purpura Am J Dis Child1988;142:508–11
  13. Calpin C, Dick P, Poon A, Feldman W. Is bone marrow aspiration needed in acute childhood idiopathic thrombo-cytopenic purpura to rule out leukemia?Arch Pediatr Ado-lesc Med 1998;152:345–7.
  14. George JN, Woolf SH, Raskob GE,et al. Idiopathic throm-bocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood1996;88:3–40
  15. Vesely S, Buchanan G, Cohen A, Raskob G, George J. Self reported diagnostic and management strategies in child-hood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology-oncology spe-cialists.J Pediatr Hematol Oncol2000;22:55-61.
  16. James N. George, Steven H. Woolf, Gary E. Raskob, Jeffrey S. Wasser, Louis M. Aledort, Penny J et al. Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology. Blood, VOl 88, NO 1 (July 1). 1996 pp 3-40.
  17. Taub JW,Warrier I, Holtkamp C, Beardsley DS, Lusher JM. Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura.Am J Hematol1995;48:104–7.
  18. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocyto-penic purpura against published guidelines.Lancet1997; 350:620–3.
  19. Tarantino MD, Madden RM, Fennewald DL, Patel CC, Bertolone SJ. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.J Pediatr1999;134:21–6 ;
  20. Blanchette V, Imbach P, Andrew M,et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocyto-penic purpura.Lancet1994;344:703–7.]
  21. Warrier I, Bussel JB, Valdez L, Barbosa J, Beardsley DS. Safety and eYcacy of low-dose intravenous immune globu-lin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol1997;19:197–201.
  22. Recommandations sur la transfusion de plaquettes: produits, indications. Afssaps, 2003. http://www.hemovigilance-cncrh.fr/Indicat/plaqreco.pdf
  23. Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediat-ric Haematology Group.Arch Dis Child1992;67:1056–8.

Similar Articles

You may also start an advanced similarity search for this article.